<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>国广有话说 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-18T16:23:28+08:00</updated>
  <subtitle>立足于客观公正，挖掘发现医药企业价值投资机会</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>创新药行业动态追踪系列研究之2020医保谈判猜想（第01期：政策点拨）【东吴医药朱国广团队】</title>
    <updated>2020-11-18T14:27:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/Y7oTnYR53A4Qdmk0cvchIw</id>
    <link href="https://mp.weixin.qq.com/s/Y7oTnYR53A4Qdmk0cvchIw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>南微医学(688029)事件点评：股权激励方案发布，彰显公司未来信心【东吴医药朱国广团队】</title>
    <updated>2020-11-17T10:52:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-17:/s/eehdcPdfTonhH9gZ4gi0oQ</id>
    <link href="https://mp.weixin.qq.com/s/eehdcPdfTonhH9gZ4gi0oQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>爱美客（300896）事件点评：利拉鲁肽临床试验获批，减肥减重产品取得积极进展【东吴医药&amp;社服零售】</title>
    <updated>2020-11-16T14:55:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/JgIxx5rXQ7MTxRmRtj8yqQ</id>
    <link href="https://mp.weixin.qq.com/s/JgIxx5rXQ7MTxRmRtj8yqQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Q4为何是医药战略性建仓最佳时机？【东吴医药朱国广团队|1115周报】</title>
    <updated>2020-11-15T13:37:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/3v9QX4VzgzFVuWnMvD1HRA</id>
    <link href="https://mp.weixin.qq.com/s/3v9QX4VzgzFVuWnMvD1HRA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亿帆医药（002019）：创新药迎来收获期，制剂等主业稳健增长【东吴医药朱国广团队】</title>
    <updated>2020-11-11T20:40:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/cqioWEQ3gGjdWzgRXu9xIQ</id>
    <link href="https://mp.weixin.qq.com/s/cqioWEQ3gGjdWzgRXu9xIQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“横看成岭侧成峰”——“秒懂”全球创新药系列研究之靶点掘金（第03期：ADC药物）【东吴医药朱国广团队】</title>
    <updated>2020-11-09T17:19:12+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/hIQiaqTlIk2bR_c9HyhJtw</id>
    <link href="https://mp.weixin.qq.com/s/hIQiaqTlIk2bR_c9HyhJtw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>冠脉支架集采落地，医疗耗材利空压制释放【东吴医药朱国广团队|1106周报】</title>
    <updated>2020-11-08T22:10:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-08:/s/3ZRzOOSiee7_Dyo4uknpkA</id>
    <link href="https://mp.weixin.qq.com/s/3ZRzOOSiee7_Dyo4uknpkA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>静待创新药医保谈判落地！【医药行业11月投资策略｜东吴医药朱国广团队】</title>
    <updated>2020-11-06T16:20:12+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/DiXexDKwWtO4iGBKWTItGg</id>
    <link href="https://mp.weixin.qq.com/s/DiXexDKwWtO4iGBKWTItGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年医药行业三季报总结专题报告： 医药Q3业绩持续恢复，医疗器械、CXO、药店强劲【东吴医药朱国广团队】</title>
    <updated>2020-11-02T00:12:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/jEbo7Bl3SDUIx_uMve6D1A</id>
    <link href="https://mp.weixin.qq.com/s/jEbo7Bl3SDUIx_uMve6D1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>年内哪些医药标的会有显著超额收益？【东吴医药朱国广团队|1030周报】</title>
    <updated>2020-11-01T18:16:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-01:/s/Zm_l0rsy7fJm1I7GUdU03A</id>
    <link href="https://mp.weixin.qq.com/s/Zm_l0rsy7fJm1I7GUdU03A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>昭衍新药三季报点评：Q3收入快速扩大，安评龙头业务持续推进【东吴医药朱国广团队】</title>
    <updated>2020-11-01T18:16:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-01:/s/48GCpIHc2Zfd4-I_c0Mvtg</id>
    <link href="https://mp.weixin.qq.com/s/48GCpIHc2Zfd4-I_c0Mvtg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>